Immuno-Oncology Clinical Trials Market By Therapy Type (Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Therapy (ACT), Monoclonal Antibodies, Oncolytic Virus Therapy, Cytokine-Based Therapy, Others), By Trial Phase (Phase I, Phase II, Phase III, Phase IV), By Cancer Type (Hematologic Malignancies {Leukemia, Lymphoma, Multiple Myeloma}, Solid Tumors {Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Head & Neck Cancer, Others}), By Design Type (Interventional Trials, Observational Studies, Expanded Access Studies), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Contract Research Organizations (CROs), Government & Non-Profit Organizations), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles and Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Immuno-Oncology Clinical Trials Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Increasing global cancer burden is driving demand for new and more effective immuno-oncology therapies

3.2.2. Growing prevalence of cancers like lung, breast, and colorectal cancer fuels trial activity

3.2.3. Rising R&D investments from pharmaceutical and biotech companies

3.3. Key industry pitfalls & challenges

3.3.1. Conducting immuno-oncology trials is expensive due to long study durations, complex trial designs

3.3.2. Finding eligible patients with specific genetic or immune profiles can be difficult, leading to delays in trial completion

3.3.3. The diverse nature of tumor microenvironments and immune responses makes it difficult to establish universal treatment protocols, affecting trial success rates

3.4. Market Opportunities

3.4.1. Growing interest in combining immune checkpoint inhibitors with targeted therapies, chemotherapy, or novel agents

3.4.2. Expansion of CAR-T and TCR therapies beyond hematologic malignancies into solid tumors

3.4.3. Advanced analytics for biomarker discovery, patient monitoring, and real-world evidence integration

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Immuno-Oncology Clinical Trials Market, Therapy Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Therapy Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Checkpoint Inhibitors

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Cancer Vaccines

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Adoptive Cell Therapy (ACT)

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Monoclonal Antibodies

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6. Oncolytic Virus Therapy

4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.7. Cytokine-Based Therapy

4.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.8. Others

4.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Immuno-Oncology Clinical Trials Market, Trial Phase Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Trial Phase, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Phase I

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Phase II

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Phase III

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Phase IV

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Immuno-Oncology Clinical Trials Market, Cancer Type Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Cancer Type, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Hematologic Malignancies

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.2.1.1. Leukemia

6.2.1.1.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.2.1.2. Lymphoma

6.2.1.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.2.1.3. Multiple Myeloma

6.2.1.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Solid Tumors

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3.1.1. Lung Cancer

6.3.1.1.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3.1.2. Breast Cancer

6.3.1.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3.1.3. Colorectal Cancer

6.3.1.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3.1.4. Prostate Cancer

6.3.1.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3.1.5. Melanoma

6.3.1.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3.1.6. Ovarian Cancer

6.3.1.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3.1.7. Pancreatic Cancer

6.3.1.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3.1.8. Head & Neck Cancer

6.3.1.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3.1.9. Others

6.3.1.9.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Immuno-Oncology Clinical Trials Market, Design Type Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Design Type, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Interventional Trials

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Observational Studies

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Expanded Access Studies

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Immuno-Oncology Clinical Trials Market, End-user Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By End-user, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Pharmaceutical & Biotechnology Type Companies

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Academic & Research Institutions

8.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.4. Contract Research Organizations (CROs)

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.5. Government & Non-Profit Organizations

8.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. Immuno-Oncology Clinical Trials Market, Region Segment Analysis

9.1. Overview

9.1.1. Global Market Revenue Share, By Region, 2025 & 2035

9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

9.2. North America

9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

9.2.2. North America Market Revenue, By Therapy Type, 2025-2035

9.2.3. North America Market Revenue, By Trial Phase, 2025-2035

9.2.4. North America Market Revenue, By Cancer Type, 2025-2035

9.2.5. North America Market Revenue, By Design Type, 2025-2035

9.2.6. North America Market Revenue, By End-user, 2025-2035

9.2.7. The U.S.

9.2.7.1. U.S. Market Revenue, By Therapy Type, 2025-2035

9.2.7.2. U.S. Market Revenue, By Trial Phase, 2025-2035

9.2.7.3. U.S. Market Revenue, By Cancer Type, 2025-2035

9.2.7.4. U.S. Market Revenue, By Design Type, 2025-2035

9.2.7.5. U.S. Market Revenue, By End-user, 2025-2035

9.2.8. Canada

9.2.8.1. Canada Market Revenue, By Therapy Type, 2025-2035

9.2.8.2. Canada Market Revenue, By Trial Phase, 2025-2035

9.2.8.3. Canada Market Revenue, By Cancer Type, 2025-2035

9.2.8.4. Canada Market Revenue, By Design Type, 2025-2035

9.2.8.5. Canada Market Revenue, By End-user, 2025-2035

9.3. Europe

9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

9.3.2. Europe Market Revenue, By Therapy Type, 2025-2035

9.3.3. Europe Market Revenue, By Trial Phase, 2025-2035

9.3.4. Europe Market Revenue, By Cancer Type, 2025-2035

9.3.5. Europe Market Revenue, By Design Type, 2025-2035

9.3.6. Europe Market Revenue, By End-user, 2025-2035

9.3.7. Germany

9.3.7.1. Germany Market Revenue, By Therapy Type, 2025-2035

9.3.7.2. Germany Market Revenue, By Trial Phase, 2025-2035

9.3.7.3. Germany Market Revenue, By Cancer Type, 2025-2035

9.3.7.4. Germany Market Revenue, By Design Type, 2025-2035

9.3.7.5. Germany Market Revenue, By End-user, 2025-2035

9.3.8. France

9.3.8.1. France Market Revenue, By Therapy Type, 2025-2035

9.3.8.2. France Market Revenue, By Trial Phase, 2025-2035

9.3.8.3. France Market Revenue, By Cancer Type, 2025-2035

9.3.8.4. France Market Revenue, By Design Type, 2025-2035

9.3.8.5. France Market Revenue, By End-user, 2025-2035

9.3.9. U.K.

9.3.9.1. U.K. Market Revenue, By Therapy Type, 2025-2035

9.3.9.2. U.K. Market Revenue, By Trial Phase, 2025-2035

9.3.9.3. U.K. Market Revenue, By Cancer Type, 2025-2035

9.3.9.4. U.K. Market Revenue, By Design Type, 2025-2035

9.3.9.5. U.K. Market Revenue, By End-user, 2025-2035

9.3.10. Italy

9.3.10.1. Italy Market Revenue, By Therapy Type, 2025-2035

9.3.10.2. Italy Market Revenue, By Trial Phase, 2025-2035

9.3.10.3. Italy Market Revenue, By Cancer Type, 2025-2035

9.3.10.4. Italy Market Revenue, By Design Type, 2025-2035

9.3.10.5. Italy Market Revenue, By End-user, 2025-2035

9.3.11. Spain

9.3.11.1. Spain Market Revenue, By Therapy Type, 2025-2035

9.3.11.2. Spain Market Revenue, By Trial Phase, 2025-2035

9.3.11.3. Spain Market Revenue, By Cancer Type, 2025-2035

9.3.11.4. Spain Market Revenue, By Design Type, 2025-2035

9.3.11.5. Spain Market Revenue, By End-user, 2025-2035

9.3.12. Rest of Europe

9.3.12.1. Rest of Europe Market Revenue, By Therapy Type, 2025-2035

9.3.12.2. Rest of Europe Market Revenue, By Trial Phase, 2025-2035

9.3.12.3. Rest of Europe Market Revenue, By Cancer Type, 2025-2035

9.3.12.4. Rest of Europe Market Revenue, By Design Type, 2025-2035

9.3.12.5. Rest of Europe Market Revenue, By End-user, 2025-2035

9.4. Asia Pacific

9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

9.4.2. Asia Pacific Market Revenue, By Therapy Type, 2025-2035

9.4.3. Asia Pacific Market Revenue, By Trial Phase, 2025-2035

9.4.4. Asia Pacific Market Revenue, By Cancer Type, 2025-2035

9.4.5. Asia Pacific Market Revenue, By Design Type, 2025-2035

9.4.6. Asia Pacific Market Revenue, By End-user, 2025-2035

9.4.7. China

9.4.7.1. China Market Revenue, By Therapy Type, 2025-2035

9.4.7.2. China Market Revenue, By Trial Phase, 2025-2035

9.4.7.3. China Market Revenue, By Cancer Type, 2025-2035

9.4.7.4. China Market Revenue, By Design Type, 2025-2035

9.4.7.5. China Market Revenue, By End-user, 2025-2035

9.4.8. Japan

9.4.8.1. Japan Market Revenue, By Therapy Type, 2025-2035

9.4.8.2. Japan Market Revenue, By Trial Phase, 2025-2035

9.4.8.3. Japan Market Revenue, By Cancer Type, 2025-2035

9.4.8.4. Japan Market Revenue, By Design Type, 2025-2035

9.4.8.5. Japan Market Revenue, By End-user, 2025-2035

9.4.9. India

9.4.9.1. India Market Revenue, By Therapy Type, 2025-2035

9.4.9.2. India Market Revenue, By Trial Phase, 2025-2035

9.4.9.3. India Market Revenue, By Cancer Type, 2025-2035

9.4.9.4. India Market Revenue, By Design Type, 2025-2035

9.4.9.5. India Market Revenue, By End-user, 2025-2035

9.4.10. Australia

9.4.10.1. Australia Market Revenue, By Therapy Type, 2025-2035

9.4.10.2. Australia Market Revenue, By Trial Phase, 2025-2035

9.4.10.3. Australia Market Revenue, By Cancer Type, 2025-2035

9.4.10.4. Australia Market Revenue, By Design Type, 2025-2035

9.4.10.5. Australia Market Revenue, By End-user, 2025-2035

9.4.11. South Korea

9.4.11.1. South Korea Market Revenue, By Therapy Type, 2025-2035

9.4.11.2. South Korea Market Revenue, By Trial Phase, 2025-2035

9.4.11.3. South Korea Market Revenue, By Cancer Type, 2025-2035

9.4.11.4. South Korea Market Revenue, By Design Type, 2025-2035

9.4.11.5. South Korea Market Revenue, By End-user, 2025-2035

9.4.12. Singapore

9.4.12.1. Singapore Market Revenue, By Therapy Type, 2025-2035

9.4.12.2. Singapore Market Revenue, By Trial Phase, 2025-2035

9.4.12.3. Singapore Market Revenue, By Cancer Type, 2025-2035

9.4.12.4. Singapore Market Revenue, By Design Type, 2025-2035

9.4.12.5. Singapore Market Revenue, By End-user, 2025-2035

9.4.13. Rest of Asia Pacific

9.4.13.1. Rest of Asia Pacific Market Revenue, By Therapy Type, 2025-2035

9.4.13.2. Rest of Asia Pacific Market Revenue, By Trial Phase, 2025-2035

9.4.13.3. Rest of Asia Pacific Market Revenue, By Cancer Type, 2025-2035

9.4.13.4. Rest of Asia Pacific Market Revenue, By Design Type, 2025-2035

9.4.13.5. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

9.5. Latin America

9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

9.5.2. Latin America Market Revenue, By Therapy Type, 2025-2035

9.5.3. Latin America Market Revenue, By Trial Phase, 2025-2035

9.5.4. Latin America Market Revenue, By Cancer Type, 2025-2035

9.5.5. Latin America Market Revenue, By Design Type, 2025-2035

9.5.6. Latin America Market Revenue, By End-user, 2025-2035

9.5.7. Brazil

9.5.7.1. Brazil Market Revenue, By Therapy Type, 2025-2035

9.5.7.2. Brazil Market Revenue, By Trial Phase, 2025-2035

9.5.7.3. Brazil Market Revenue, By Cancer Type, 2025-2035

9.5.7.4. Brazil Market Revenue, By Design Type, 2025-2035

9.5.7.5. Brazil Market Revenue, By End-user, 2025-2035

9.5.8. Argentina

9.5.8.1. Argentina Market Revenue, By Therapy Type, 2025-2035

9.5.8.2. Argentina Market Revenue, By Trial Phase, 2025-2035

9.5.8.3. Argentina Market Revenue, By Cancer Type, 2025-2035

9.5.8.4. Argentina Market Revenue, By Design Type, 2025-2035

9.5.8.5. Argentina Market Revenue, By End-user, 2025-2035

9.5.9. Mexico

9.5.9.1. Mexico Market Revenue, By Therapy Type, 2025-2035

9.5.9.2. Mexico Market Revenue, By Trial Phase, 2025-2035

9.5.9.3. Mexico Market Revenue, By Cancer Type, 2025-2035

9.5.9.4. Mexico Market Revenue, By Design Type, 2025-2035

9.5.9.5. Mexico Market Revenue, By End-user, 2025-2035

9.5.10. Rest of Latin America

9.5.10.1. Rest of Latin America Market Revenue, By Therapy Type, 2025-2035

9.5.10.2. Rest of Latin America Revenue, By Trial Phase, 2025-2035

9.5.10.3. Rest of Latin America Market Revenue, By Cancer Type, 2025-2035

9.5.10.4. Rest of Latin America Market Revenue, By Design Type, 2025-2035

9.5.10.5. Rest of Latin America Market Revenue, By End-user, 2025-2035

9.6. MEA

9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

9.6.2. MEA Market Revenue, By Therapy Type, 2025-2035

9.6.3. MEA Market Revenue, By Trial Phase, 2025-2035

9.6.4. MEA Market Revenue, By Cancer Type, 2025-2035

9.6.5. MEA Market Revenue, By Design Type, 2025-2035

9.6.6. MEA Market Revenue, By End-user, 2025-2035

9.6.7. GCC Countries

9.6.7.1. GCC Countries Market Revenue, By Therapy Type, 2025-2035

9.6.7.2. GCC Countries Market Revenue, By Trial Phase, 2025-2035

9.6.7.3. GCC Countries Market Revenue, By Cancer Type, 2025-2035

9.6.7.4. GCC Countries Market Revenue, By Design Type, 2025-2035

9.6.7.5. GCC Countries Market Revenue, By End-user, 2025-2035

9.6.8. South Africa

9.6.8.1. South Africa Market Revenue, By Therapy Type, 2025-2035

9.6.8.2. South Africa Market Revenue, By Trial Phase, 2025-2035

9.6.8.3. South Africa Market Revenue, By Cancer Type, 2025-2035

9.6.8.4. South Africa Market Revenue, By Design Type, 2025-2035

9.6.8.5. South Africa Market Revenue, By End-user, 2025-2035

9.6.9. Rest of Middle-East & Africa

9.6.9.1. Rest of Middle-East & Africa Market Revenue, By Therapy Type, 2025-2035

9.6.9.2. Rest of Middle-East & Africa Market Revenue, By Trial Phase, 2025-2035

9.6.9.3. Rest of Middle-East & Africa Market Revenue, By Cancer Type, 2025-2035

9.6.9.4. Rest of Middle-East & Africa Market Revenue, By Design Type, 2025-2035

9.6.9.5. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

10. Company Profile

10.1. Merck & Co., Inc.

10.1.1. Business Overview

10.1.2. Financial Performance

10.1.3. Product/Service Offerings

10.1.4. Strategies & recent developments

10.1.5. SWOT Analysis

10.2. Bristol-Myers Squibb Company

10.2.1. Business Overview

10.2.2. Financial Performance

10.2.3. Product/Service Offerings

10.2.4. Strategies & recent developments

10.2.5. SWOT Analysis

10.3. Genentech, Inc.

10.3.1. Business Overview

10.3.2. Financial Performance

10.3.3. Product/Service Offerings

10.3.4. Strategies & recent developments

10.3.5. SWOT Analysis

10.4. AstraZeneca plc

10.4.1. Business Overview

10.4.2. Financial Performance

10.4.3. Product/Service Offerings

10.4.4. Strategies & recent developments

10.4.5. SWOT Analysis

10.5. Pfizer Inc.

10.5.1. Business Overview

10.5.2. Financial Performance

10.5.3. Product/Service Offerings

10.5.4. Strategies & recent developments

10.5.5. SWOT Analysis

10.6. Novartis AG

10.6.1. Business Overview

10.6.2. Financial Performance

10.6.3. Product/Service Offerings

10.6.4. Strategies & recent developments

10.6.5. SWOT Analysis

10.7. Gilead Sciences, Inc.

10.7.1. Business Overview

10.7.2. Financial Performance

10.7.3. Product/Service Offerings

10.7.4. Strategies & recent developments

10.7.5. SWOT Analysis

10.8. Johnson & Johnson

10.8.1. Business Overview

10.8.2. Financial Performance

10.8.3. Product/Service Offerings

10.8.4. Strategies & recent developments

10.8.5. SWOT Analysis

10.9. Amgen Inc.

10.9.1. Business Overview

10.9.2. Financial Performance

10.9.3. Product/Service Offerings

10.9.4. Strategies & recent developments

10.9.5. SWOT Analysis

10.10. Moderna, Inc.

10.10.1. Business Overview

10.10.2. Financial Performance

10.10.3. Product/Service Offerings

10.10.4. Strategies & recent developments

10.10.5. SWOT Analysis

10.11. Eli Lilly and Company

10.11.1. Business Overview

10.11.2. Financial Performance

10.11.3. Product/Service Offerings

10.11.4. Strategies & recent developments

10.11.5. SWOT Analysis

10.12. Sanofi S.A.

10.12.1. Business Overview

10.12.2. Financial Performance

10.12.3. Product/Service Offerings

10.12.4. Strategies & recent developments

10.12.5. SWOT Analysis

10.13. GlaxoSmithKline plc (GSK)

10.13.1. Business Overview

10.13.2. Financial Performance

10.13.3. Product/Service Offerings

10.13.4. Strategies & recent developments

10.13.5. SWOT Analysis

10.14. Regeneron Pharmaceuticals, Inc.

10.14.1. Business Overview

10.14.2. Financial Performance

10.14.3. Product/Service Offerings

10.14.4. Strategies & recent developments

10.14.5. SWOT Analysis

10.15. BeiGene, Ltd.

10.15.1. Business Overview

10.15.2. Financial Performance

10.15.3. Product/Service Offerings

10.15.4. Strategies & recent developments

10.15.5. SWOT Analysis